List of Excipients in Branded Drug IDARUBICIN HYDROCHLORIDE

Generic Drugs Containing IDARUBICIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	idarubicin hydrochloride	0143-9217	GLYCERIN
Hikma Pharmaceuticals USA Inc	idarubicin hydrochloride	0143-9217	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	idarubicin hydrochloride	0143-9217	WATER
Hikma Pharmaceuticals USA Inc	idarubicin hydrochloride	0143-9306	GLYCERIN
Hikma Pharmaceuticals USA Inc	idarubicin hydrochloride	0143-9306	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	idarubicin hydrochloride	0143-9306	WATER

What are the Most Frequently-Used Excipients in IDARUBICIN HYDROCHLORIDE?

# Of NDCs	Excipient
4	GLYCERIN
2	HYDROCHLORIC ACID
4	WATER

Idarubicin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Idarubicin hydrochloride is an established anthracycline used primarily in acute myeloid leukemia. Its active-ingredient patents and regulatory exclusivities are historical, so commercial differentiation depends on formulation performance, supply reliability, handling safety, and lifecycle products rather than a new chemical entity strategy. The strongest opportunities are ready-to-use injectable presentations, improved stability, low-overfill containers, closed-system administration compatibility, and differentiated formulations that reduce occupational exposure or preparation burden.

What is the FDA regulatory status of idarubicin hydrochloride?

Idarubicin hydrochloride is an FDA-approved cytotoxic oncology drug administered intravenously. The branded product Idamycin PFS and generic idarubicin hydrochloride injections are supplied as sterile injectable products for hospital use. The FDA-approved indication is generally in combination with other antileukemic agents for adults with acute myeloid leukemia, including previously untreated disease in applicable labeling. [1]

Key regulatory characteristics

Attribute	Commercial and regulatory implication
Active ingredient	Idarubicin hydrochloride
Drug class	Anthracycline antineoplastic
Primary use	Acute myeloid leukemia
Route	Intravenous
Product type	Sterile injectable solution or powder for solution, depending on market
Administration setting	Hospital oncology and hematology units
Regulatory pathway for generics	ANDA, subject to applicable reference-product and bioequivalence requirements
Biologic status	Small molecule; biosimilar pathway does not apply
Main formulation risks	Cytotoxic handling, precipitation, container compatibility, stability, light exposure, and dosing accuracy

FDA labeling identifies a ready-to-use injectable presentation containing idarubicin hydrochloride, sodium chloride, water for injection, and hydrochloric acid used for pH adjustment. The labeled concentration is commonly 1 mg/mL, although presentations and excipient composition vary by manufacturer and jurisdiction. [1,2]

European product information also includes powder-for-solution presentations containing lactose monohydrate. This creates a meaningful formulation distinction between liquid products and lyophilized or powder products. [3]

Which excipients are used in idarubicin hydrochloride injections?

The principal excipient strategies are simple aqueous saline formulation and powder-for-reconstitution formulation.

Liquid idarubicin hydrochloride formulation

A representative ready-to-use solution contains:

Component	Function
Idarubicin hydrochloride	Active pharmaceutical ingredient
Sodium chloride	Isotonicity adjustment
Water for injection	Vehicle
Hydrochloric acid	pH adjustment

The liquid approach minimizes pharmacy preparation and eliminates reconstitution steps. It requires close control of pH, particulate matter, container interaction, extractables, leachables, and long-term chemical stability. [1,2]

Powder-for-solution formulation

Powder presentations may use lactose monohydrate as a bulking agent or stabilizing excipient. The product is reconstituted before dilution and administration. Powder products can improve transport stability and reduce the risk of degradation during storage, but they add preparation time and increase handling steps for pharmacy staff. [3]

Excipients that require careful evaluation

Idarubicin is a potent cytotoxic compound. Commercial development should evaluate:

• Surfactant compatibility and the risk of adsorption to administration systems.
• Buffer selection and pH-dependent degradation.
• Oxidative degradation and the effect of oxygen exposure.
• Container closure compatibility.
• Visible and subvisible particulate formation.
• Sorption to polymeric syringes, bags, and tubing.
• Light sensitivity during storage and administration.
• Residual solvents and elemental impurities.
• Extractables and leachables from elastomers and plastic components.
• Compatibility with sodium chloride and dextrose dilution vehicles.
• Compatibility with closed-system transfer devices.

The product label warns against mixing idarubicin with incompatible solutions, including alkaline solutions, and identifies incompatibility concerns with heparin. [1] These restrictions create a commercial opportunity for validated administration-system compatibility data.

What formulation patents could protect idarubicin hydrochloride products?

The original idarubicin compound and basic therapeutic use are unlikely to provide a meaningful new-product exclusivity strategy because the molecule has been commercially available for decades. New patent value would more likely arise from formulation, packaging, manufacturing, or administration claims.

Formulation patent opportunities

Potential claim categories include:

1. Stable aqueous idarubicin solutions within a defined pH range.
2. Preservative-free liquid formulations with extended shelf life.
3. Low-concentration or high-concentration presentations that reduce preparation steps.
4. Lyophilized compositions with defined bulking agents and reconstitution performance.
5. Container systems that reduce adsorption or leachables.
6. Premixed infusion bags or ready-to-administer syringes.
7. Liposomal or nanoparticle formulations.
8. Formulations that reduce free idarubicin exposure during preparation.
9. Drug-device combinations using closed-system transfer technology.
10. Specific impurity profiles and manufacturing controls.

A formulation patent must establish a measurable technical advantage. Generic claims covering idarubicin, water, sodium chloride, and pH adjustment would face validity and obviousness pressure because the basic composition is disclosed in regulatory labeling and earlier pharmaceutical literature.

Manufacturing and process claims

Manufacturing IP may be stronger when it protects:

• A reproducible idarubicin hydrochloride crystallization process.
• Control of regioisomeric or degradation impurities.
• A sterile filtration and aseptic filling process.
• A lyophilization cycle that improves reconstitution time.
• Low-overfill filling methods for high-value cytotoxic product.
• A container closure system with reduced drug loss.
• In-process controls for potency and particulate matter.

Process patents have commercial value when they produce a lower-cost, higher-yield, or more stable product. They are less useful against a competitor that can manufacture the same product through a noninfringing route.

When does idarubicin hydrochloride lose exclusivity?

Idarubicin hydrochloride has already lost the exclusivity associated with its original small-molecule approval. The current commercial question is therefore not the loss of originator exclusivity but the absence of meaningful barriers to generic competition.

Exclusivity timeline

Event	Strategic significance
Original idarubicin development and approval	Established the anthracycline product category
Expiration of original compound and early-use patents	Opened the market to generic manufacturers
Generic injectable approvals	Shifted competition toward price, supply, quality, and hospital contracting
Current market	Primarily a mature injectable market with limited brand premium

FDA marketing exclusivity and patent protection must be assessed by product and jurisdiction. A specific current expiration date cannot be assigned to every marketed presentation without matching each National Drug Code, application, Orange Book entry, and listed patent. The commercial reality is that idarubicin hydrochloride is a mature generic product rather than an active originator-exclusivity market.

What is the Orange Book status of idarubicin hydrochloride?

The FDA Orange Book is the relevant source for approved small-molecule products, therapeutic equivalence evaluations, and any listed patents or exclusivity periods. Idarubicin hydrochloride should be reviewed by reference product, dosage form, strength, and application number rather than by active ingredient alone. [4]

Orange Book implications

For a generic idarubicin hydrochloride injection:

• Paragraph IV risk is generally limited if no unexpired listed patents cover the reference product.
• A Paragraph III certification may apply if an unexpired listed patent remains but the generic agrees to launch after expiration.
• A Paragraph I or II certification may apply where no relevant patent is listed or where the patent information is not applicable.
• Formulation patents not listed in the Orange Book can still create litigation risk if they cover an approved product or method of use.
• Device, packaging, manufacturing, and unlisted process patents may affect freedom to operate without blocking ANDA approval directly.

Because idarubicin is not a biologic, biosimilar litigation and the Biologics Price Competition and Innovation Act pathway do not apply.

Are Paragraph IV challenges likely for idarubicin hydrochloride?

Paragraph IV activity is unlikely to be the primary competitive issue for a mature idarubicin product unless a newer formulation has generated an unexpired listed patent. Standard injectable idarubicin hydrochloride products have limited commercial incentive for repeated patent challenges because the market is relatively narrow and price competition is already established.

The more relevant risks are:

• A new ready-to-use formulation with an Orange Book-listed composition patent.
• A proprietary liposomal or long-acting formulation.
• A patent covering a specific method of reducing cardiotoxicity or improving leukemia treatment.
• A 505(b)(2) product relying partly on published data but claiming a differentiated formulation.
• A patent dispute over container closure or administration technology.

A new formulation sponsor could obtain a period of market protection through a 505(b)(2) application if it develops a clinically or pharmaceutically meaningful difference. That pathway would not recreate new chemical entity exclusivity, but it could support limited regulatory exclusivity and formulation-specific patent protection.

What excipient strategies offer the strongest commercial opportunities?

Ready-to-use liquid products

A ready-to-use product is the most direct commercial opportunity. It can reduce pharmacy preparation, shorten handling time, and lower reconstitution errors. A successful product would need:

• Long refrigerated and, ideally, controlled-room-temperature stability.
• Low particulate formation.
• Compatibility with common infusion bags and tubing.
• Clear labeling for dilution and administration.
• Container sizes aligned with common oncology doses.
• Cytotoxic handling instructions and tamper-evident packaging.

A premixed bag could compete on workflow efficiency rather than active-ingredient price.

Improved lyophilized product

A powder product can target markets where cold-chain reliability is limited or where liquid stability is inadequate. Differentiation could come from:

• Faster reconstitution.
• Reduced foaming.
• Lower residual moisture.
• Improved stability after reconstitution.
• Smaller vial size.
• More consistent recovery of the labeled dose.

Lactose-based products may require careful assessment for patient-specific excipient restrictions, although lactose quantities in injectable oncology products are generally low.

Low-sorption packaging

Idarubicin is administered at low absolute quantities relative to the volume of an infusion system. Drug loss through adsorption or surface interaction can therefore affect delivered dose. A low-sorption syringe, vial, bag, or tubing system could support a defensible product position if supported by comparative recovery studies.

Potential materials include specialized cyclic olefin polymers, coated elastomers, and low-binding tubing. The commercial value would depend on demonstrating improved dose recovery without introducing new extractables or manufacturing complexity.

Closed-system administration package

A formulation packaged with a compatible closed-system transfer device could reduce occupational exposure and improve pharmacy workflow. The strongest product would combine:

• A validated container closure.
• A transfer connector.
• A ready-to-administer or ready-to-dilute format.
• Compatibility data for common oncology pumps.
• Standardized disposal and spill-control procedures.

This is more likely to generate device or combination-product IP than a conventional excipient patent.

Liposomal and nanoparticle formulations

Liposomal idarubicin could seek improved tissue distribution, altered pharmacokinetics, reduced cardiotoxicity, or enhanced antitumor exposure. These products would have higher development costs and may require clinical studies to establish meaningful benefit. They would compete with established anthracyclines and other liposomal products, including liposomal doxorubicin.

The formulation challenge is substantial. The sponsor would need to control particle size, encapsulation efficiency, release rate, sterility, aggregation, leakage, and scale-up reproducibility. This opportunity is commercially attractive only if the product demonstrates a clinically relevant advantage.

How does idarubicin compare with competing anthracyclines?

Product	Main competitive position	Excipient and formulation opportunity
Idarubicin	AML-focused anthracycline	Ready-to-use injection, stability, low-sorption packaging
Daunorubicin	AML and acute leukemia use	Similar hospital workflow and cytotoxic-handling needs
Doxorubicin	Broad oncology use and larger market	Greater opportunity for liposomal and delivery-system competition
Liposomal doxorubicin	Differentiated pharmacokinetics and delivery	Higher barrier but stronger formulation precedent
Mitoxantrone	Alternative antineoplastic use	Different toxicity and formulation profile

Idarubicin has a narrower market than doxorubicin, which limits the commercial ceiling for a premium excipient platform. Its focused use in AML can still support hospital value if the product reduces preparation time, waste, exposure risk, or dosing variability.

Which companies are challenging idarubicin hydrochloride?

The market is primarily composed of generic injectable manufacturers and contract suppliers rather than companies pursuing aggressive originator-style patent litigation. Competition typically occurs through:

• ANDA-approved injectable products.
• Hospital group purchasing contracts.
• Shortage-response supply.
• Contract manufacturing.
• Regional regulatory approvals.
• Differentiated vial sizes and packaging.

Company-level market share and current supplier rankings require product-level commercial data. Public financial reports generally do not disclose idarubicin revenue separately because the product is usually included within broader hospital injectable or generic portfolios.

What patent litigation affects idarubicin hydrochloride?

No major current patent dispute should be assumed solely from the existence of an idarubicin hydrochloride product. Litigation risk must be tied to a specific formulation, application, patent number, and defendant.

The most plausible disputes would involve:

• A newly developed liposomal formulation.
• A ready-to-use solution with a patented stabilizer system.
• A container or administration system.
• A method-of-use claim for a defined AML population.
• A 505(b)(2) product with an approved formulation difference.

For a conventional idarubicin hydrochloride injection, commercial risk is more likely to arise from manufacturing interruptions, regulatory observations, or hospital contracting than from active patent litigation.

What generic launch scenarios exist for idarubicin hydrochloride?

Standard low-cost generic

This product competes on acquisition price and supply continuity. It has low differentiation and limited patent exposure but can face margin compression.

Supply-reliability product

A manufacturer can charge a modest premium by offering multiple manufacturing sites, larger inventory, and consistent hospital allocation. This strategy is relevant because sterile injectable markets are vulnerable to shortages.

Ready-to-use product

A ready-to-use solution or premixed bag can compete on labor savings and reduction of preparation steps. The product may support a formulation patent if its stability and excipient system are technically distinct.

Combination product

A formulation packaged with a compatible transfer or administration device may create a stronger commercial position. It would require integrated regulatory, quality, and device-management capabilities.

How strong is the patent estate for idarubicin hydrochloride?

The underlying idarubicin patent estate is weak as a source of current exclusivity because the active ingredient is old and generic competition is established. The stronger potential lies in newly created IP around:

• Stable liquid compositions.
• Lyophilized cakes and reconstitution systems.
• Low-binding containers.
• Cytotoxic containment.
• Liposomal delivery.
• Manufacturing impurity control.
• Specific clinical dosing regimens.

Patent strength depends on claim scope, unexpected results, freedom from prior art, and the ability to detect infringement. Composition claims are easier to enforce than manufacturing-process claims, but they face greater prior-art scrutiny. Device and packaging claims can be commercially useful but may not prevent a competitor from selling a conventional injectable.

What geographic markets offer the best opportunity?

The United States offers the clearest regulatory framework for ANDA and 505(b)(2) products, but conventional generic price competition is intense. Europe has fragmented national procurement and different presentations, including powder formulations. Emerging markets may value powder products and room-temperature stability because of distribution constraints.

A regional excipient strategy should match the product format to the supply chain:

Market condition	Preferred format
High pharmacy labor costs	Ready-to-use solution or premixed bag
Cold-chain constraints	Stable powder or lyophilized product
High cytotoxic-handling controls	Closed-system package
Strong hospital tender competition	Reliable low-cost generic
Limited oncology pharmacy infrastructure	Simple reconstitution and clear dosing format

Key Takeaways

• Idarubicin hydrochloride is a mature small-molecule oncology product with no biosimilar pathway.
• The standard excipient system is simple: sodium chloride, water for injection, and pH adjustment with hydrochloric acid in representative liquid products.
• Powder formulations may use lactose monohydrate and offer a stability-oriented alternative.
• The strongest commercial opportunities are ready-to-use products, improved reconstitution, low-sorption packaging, and closed-system administration.
• Conventional active-ingredient patent protection is unlikely to support a new commercial strategy.
• New value would need to come from formulation, container, process, device, or clinically differentiated delivery IP.
• Paragraph IV risk is limited for conventional products but may become relevant for newly patented formulations.
• Revenue exposure is difficult to isolate because manufacturers generally report idarubicin within broader generic injectable portfolios.
• The principal competitive risks are price erosion, sterile manufacturing disruption, shortages, and hospital contracting.
• A premium product requires measurable workflow, stability, safety, or dose-recovery benefits.

FAQs

Is idarubicin hydrochloride a biologic that can face biosimilar competition?

No. Idarubicin hydrochloride is a synthetic small-molecule anthracycline. Competition occurs through generic drug applications rather than biosimilar applications.

Which excipient is most important for liquid idarubicin stability?

The formulation pH and the overall aqueous environment are critical. Sodium chloride supports isotonicity, while hydrochloric acid is used for pH adjustment in representative products. Stability must be demonstrated through real-time and accelerated studies.

Can a new idarubicin formulation receive 505(b)(2) approval?

Potentially. A sponsor may pursue 505(b)(2) if the product relies partly on an approved idarubicin product or published information while introducing a distinct formulation, delivery system, or route-related feature. Regulatory eligibility depends on the specific product and development package.

Is a liposomal idarubicin product commercially viable?

It could be viable if it demonstrates a clinically meaningful advantage, such as improved exposure, reduced toxicity, or better administration performance. The development cost and clinical burden would be materially higher than for a conventional generic injection.

What is the most defensible idarubicin formulation patent strategy?

A formulation patent supported by comparative data is generally more defensible than a broad claim to idarubicin with routine excipients. Strong candidates include demonstrated stability improvements, reduced drug loss, improved reconstitution, or a defined delivery system with measurable performance benefits.

References

1. U.S. Food and Drug Administration. (n.d.). Idamycin PFS: Idarubicin hydrochloride injection prescribing information. FDA. https://www.accessdata.fda.gov/

2. National Library of Medicine. (n.d.). Idarubicin hydrochloride injection. DailyMed. https://dailymed.nlm.nih.gov/

3. European Medicines Agency. (n.d.). Zavedos: Summary of product characteristics. EMA. https://www.ema.europa.eu/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book